A Phase Ib Trial of Combined Febuxostat and Inosine Therapy in Patients With Parkinson's Disease

Not Applicable

Recruiting

• Conditions: Parkinson's Disease (PD)
• Interventions: Drug: Febuxostat; Drug: Inosine

• Registration Number: NCT07170475
• Lead Sponsor: Fujita Health University

Brief Summary

This study will test the safety of twice-daily oral dosing of combined febuxostat and inosine in 24 patients with Parkinson's disease. Participants will receive one of the four regimens, taken twice daily for 12 weeks:

Who can join: Adults with early-stage Parkinson's disease on stable medication regimens.

What participants do:

* Take their assigned dose twice daily (morning and evening) for 12 weeks.

* Visit the clinic at baseline and weeks 4, 8, and 12 for blood tests (including hypoxanthine), exams, and questionnaires.

* Keep a simple diary of any side effects or changes in daily activities.

Risks and benefits: Possible side effects include mild gastrointestinal upset, headache, or elevated uric acid levels. While direct benefit is not guaranteed, this safety data will inform future Parkinson's disease treatments.

Learn more: Contact \[site-specific contact info\] for details on eligibility and enrollment.

Detailed Description

Not available

Study Timeline

• Study Start: 2025-06-27
• Status Verified: 2025-09
• Study First Submitted: 2025-09-07
• Study First Submitted QC: 2025-09-07
• Last Update Submitted: 2025-09-07
• Study First Posted: 2025-09-12
• Last Update Posted: 2025-09-12
• Primary Completion: 2026-03-31
• Study Completion: 2026-07-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

1. Able to provide voluntary written informed consent.

2. Receiving stable Parkinson's disease medication (no changes in type or dose) for at least 3 months before enrollment.

3. Age 18 to 80 years at the time of consent.

4. Diagnosed with Parkinson's disease by a specialist according to MDS-PD diagnostic criteria, and at pre-enrollment screening, all of the following are met:

   1. Hoehn-Yahr stage (ON state) 1 to 3
   2. MDS-UPDRS Part III (ON state) score 10 to 35
   3. Mini-Mental State Examination (MMSE) score ≥ 24

Exclusion Criteria

1. Requires almost total assistance in daily life and is unable to walk or stand unaided.
2. Currently taking azathioprine, mercaptopurine hydrate, vidarabine, didanosine, or rosuvastatin.
3. Used febuxostat, allopurinol, or topiroxostat within 3 months before study start.
4. Taking any supplement containing inosine.
5. Started any new Parkinson's disease medication or therapy within 3 months before enrollment.
6. Serum creatinine >1.5× upper limit of normal (ULN), or AST (GOT) or ALT (GPT) >2× ULN at screening.
7. History of surgical treatment for Parkinson's disease.
8. History of or comorbid hypersensitivity/allergy to any ingredient of the investigational drugs.
9. Participation in another clinical trial involving an unapproved drug within 30 days before consent, or currently enrolled in another interventional study.
10. Pregnant or breastfeeding, or unwilling/unable to use reliable contraception during the study period.
11. Positive test at screening for HIV, HBV, HTLV-1, or syphilis; **HCV antibody-positive with undetectable HCV RNA** is allowed.
12. Unable to take the investigational drugs orally without changing the dosage form.
13. Gastrointestinal disease or prior GI surgery that may affect drug absorption, as judged by the investigator.
14. Psychiatric disorder or symptoms that interfere with daily life and make study participation difficult.
15. Unable to complete assessments or questionnaires independently.
16. Any other condition that, in the investigator's judgment, would make participation unsafe or inappropriate.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group 1 - Febuxostat + Inosine （Dose Level 1)	Febuxostat	Participants receive febuxostat and inosine (Dose Level 1) orally, twice daily (once in the morning and once in the evening) for 12 weeks.
Group 1 - Febuxostat + Inosine （Dose Level 1)	Inosine	Participants receive febuxostat and inosine (Dose Level 1) orally, twice daily (once in the morning and once in the evening) for 12 weeks.
Group 2 - Febuxostat + Inosine (Dose Level 2)	Febuxostat	Participants receive febuxostat and inosine (Dose Level 2) orally, twice daily (once in the morning and once in the evening) for 12 weeks.
Group 2 - Febuxostat + Inosine (Dose Level 2)	Inosine	Participants receive febuxostat and inosine (Dose Level 2) orally, twice daily (once in the morning and once in the evening) for 12 weeks.
Group 3 - Febuxostat + Inosine (Dose Level 3)	Febuxostat	Participants receive febuxostat and inosine (Dose Level 3) orally, twice daily (once in the morning and once in the evening) for 12 weeks.
Group 3 - Febuxostat + Inosine (Dose Level 3)	Inosine	Participants receive febuxostat and inosine (Dose Level 3) orally, twice daily (once in the morning and once in the evening) for 12 weeks.
Group 4 - Febuxostat + Inosine (Dose Level 4)	Febuxostat	Participants receive febuxostat and inosine (Dose level 4) orally, twice daily (once in the morning and once in the evening) for 12 weeks.
Group 4 - Febuxostat + Inosine (Dose Level 4)	Inosine	Participants receive febuxostat and inosine (Dose level 4) orally, twice daily (once in the morning and once in the evening) for 12 weeks.

Primary Outcome Measures

Name	Time	Method
Change in plasma hypoxanthine concentration from baseline to Week 12	12 weeks	The difference in plasma hypoxanthine level (µmol/L) between pre-dose at Day 0 and Week 12 visit.

Secondary Outcome Measures

Name	Time	Method
Change in plasma hypoxanthine concentration from baseline to Week 4	4 weeks	The difference in plasma hypoxanthine level between pre-dose at Day 0 and Week 4 visit.
Change in cerebrospinal fluid (CSF) hypoxanthine concentration from baseline to Week 12	12 weeks	The difference in CSF hypoxanthine level between the pre-dose at Day 0 and the Week 12 visit.
Change in MDS-UPDRS Part III score from baseline to Week 12	12 weeks	The difference in Movement Disorder Society-Unified Parkinson's Disease Rating Scale motor examination (ON state) score between Day 0 and Week 12.
Change in Mini-Mental State Examination (MMSE) score from baseline to Week 12	12 weeks	The difference in MMSE score between Day 0 and Week 12.
Change in Geriatric Depression Scale-15 (GDS-15) score from baseline to Week 12	12 weeks	The difference in GDS-15 score between Day 0 and Week 12.

Trial Locations

Locations (1)

Fujita Health University; 🇯🇵 Toyoake, Aichi-ken, Japan